The involvement of this SLC1A5-glutamine axis also supports the development of therapeutic interventions against this preferentially upregulated pathway in cancer and in this regard SLC1A5 and glutaminase inhibitors are already in experimental development. The gene discussed is GLS; the disease is cancer.